A new clinical trial, designed and led by Jennifer Sasson, MD, with the School of Medicine Division of Infectious Diseases and International Health, suggests a monoclonal antibody used to treat asthma and eczema can improve survival for patients with moderate to severe COVID-19. The small trial found that dupilumab improved patient survival at 60 days and reduced the number of patients who needed intensive care. Almost 90% of patients who received dupilumab in the randomized trial were alive at 60 days, compared with 76.2% of patients who received a placebo. A larger multi-institution study is currently being designed which, if successful, may offer a new treatment option for appropriate patients with COVID-19 and possibly other viral pneumonias.
Dr. Sasson and team published their findings in the journal Open Forum of Infectious Diseases.
Read more in UVAHealth Newsroom.